Lumohs

About the offering

Lumohs is a vertically integrated medical device platform that combines touchless blade handling, integrated illumination, and connected software to modernize procedural safety in aesthetics, dermatology, and minor surgery. Built by Dr. Steven Hacker—a dermatologist with 30+ years of clinical practice, 30+ patents, and prior exits including Skinstore.com (eventually acquired by Walgreens) and PassportMD—the platform replaces manual blade loading and ejection with a proprietary cartridge system that eliminates direct contact with exposed surgical blades. Thousands of first-generation devices have been sold, second-generation devices have launched with strong upgrade conversion rates and pre-order demand, and the company has established manufacturing, regulatory pathways, and operational infrastructure. The Wefunder campaign has raised $875,500 from 23+ investors, with notable personal investments from Mark Templeton (former CEO of Citrix Systems and Digital Ocean) and Sunil Potti (Venture Partner at Wing VC, former head of Google's security business). Total prior funding exceeds $2M from executives including former CEOs of Citrix, Digital Ocean, and PPOM (health insurance). The Problem Clinicians and medical staff routinely handle exposed surgical blades during millions of minor procedures performed daily across aesthetics, dermatology, and minor surgery. Manual blade loading and ejection creates an unavoidable occupational hazard—hand lacerations, blood exposure, trips to urgent care or the ER, lost workdays, workers' compensation claims, and liability for clinics. These injuries are not the result of complex medical decisions; they occur during routine interaction with exposed blades. Despite approximately 150,000 licensed estheticians performing roughly 150,000 dermaplaning procedures per day in the US alone (before accounting for all other surgical blade use), the fundamental instrument—the handle—has barely evolved, and blade handling remains entirely manual. Simultaneously, procedural visibility during minor procedures is often limited. Lighting is inconsistent, obstructed by hand shadowing, prohibitively expensive, or unavailable in many real-world clinical environments. These dual problems—unsafe blade handling and inadequate illumination—compound across high-volume practices, reducing productivity, increasing costs, and introducing operational friction into routine workflows. The Solution Lumohs redesigns the procedural workflow rather than improving a single component. The platform addresses both core problems simultaneously. Touchless blade handling replaces manual loading and ejection with a proprietary cartridge system that removes direct contact with exposed blades entirely. Integrated illumination delivers consistent, on-axis light directly from the instrument to the point of care, eliminating hand shadowing and external lighting dependencies. The platform is designed as a connected system with future versions integrating Bluetooth connectivity, a mobile application, and cloud data infrastructure. During procedures like dermaplaning, the device can capture procedural telemetry (blade angle, motion patterns, stroke cadence, session duration, lighting settings), which paired with AI facial scans can measure objective skin outcomes (texture, pores, moisture, radiance, redness). This creates a unique dataset linking technique to measurable results. The company is developing "GlowScore," a performance metric that converts session data and skin outcomes into a score reflecting technique quality and skin improvement—transforming dermaplaning from an artisanal technique into a measurable procedure. The expansion roadmap includes a Single-Use Sterile Handle for environments where reusable tools are impractical (clinics, emergency response, military medicine, field medical settings), extending the same touchless blade-handling system and integrated illumination to disposable workflows. Business Model Lumohs operates a razor-and-blade platform model. Hardware devices drive initial adoption, proprietary consumable cartridges create recurring usage revenue (clinicians must purchase Lumohs-specific cartridges for ongoing procedures), and software-enabled workflows support training, procedural consistency, and outcome tracking. This structure transforms a historically commoditized instrument (the surgical handle) into a platform with durable recurring revenue. The vertically integrated manufacturing model—Nano Surgical owns all molds, tooling, and device designs outright with FDA-compliant US-based manufacturing—provides control over production quality, cost structure, and rapid iteration without dependency on third-party IP. The aesthetics market serves as the beachhead due to its high procedure volume and rapid adoption of new professional tools, with natural expansion into dermatology, surgery, emergency medicine, and defense applications using the same platform architecture. Traction Thousands of first-generation lumohs devices have been sold into the professional and clinical market. Second-generation devices have launched with strong paid upgrade conversion rates and pre-order demand—indicating existing customers are willing to pay for improved versions, a powerful retention and expansion signal. Manufacturing, regulatory pathways, and operational infrastructure are established. The company holds more than 20 issued patents with a dozen more pending, primarily utility patents covering blade loading mechanisms, illumination systems, and cartridge architecture. The Wefunder campaign has raised $875,500 from 23+ investors—an average of approximately $38,000 per investor, indicating predominantly sophisticated, high-conviction participation. Prior funding exceeds $2M from notable executives. The company has 4 posts and 8 investor reviews. The founder has 30+ patents across his career and prior exits including Skinstore.com (Walgreens). The company states it is "no longer searching for product-market fit" and is focused on scaling production, expanding distribution, and increasing recurring consumable usage. No specific revenue figures, unit sales, consumable reorder rates, or financial metrics were disclosed. Market Opportunity Approximately 150,000 licensed estheticians perform roughly 150,000 dermaplaning procedures per day in the US, representing an enormous volume of daily blade-handling events before accounting for all other surgical blade use across dermatology, minor surgery, emergency medicine, and military medicine. The aesthetics market has grown rapidly over the past decade. The broader addressable market encompasses every clinical environment where surgical blades are handled manually—spanning aesthetics, dermatology, general surgery, emergency rooms, military field medicine, and potentially robotic/hybrid surgical settings. The platform's design as a touchless blade-handling system (rather than a single-use cosmetic tool) creates long-term enterprise optionality. Industry shifts supporting adoption include growing focus on occupational safety, staffing shortages making injuries more costly, and increasing expectations for connected devices and measurable outcomes across healthcare. Team President and CEO Dr. Steven Hacker is a dermatologist with 30+ years of clinical practice, founder of multiple companies with prior exits including Skinstore.com (eventually owned by Walgreens) and PassportMD, and holder of over 30 patents. He built lumohs to solve a problem he experienced firsthand in his own practice over three decades. VP of Product Development Zack Monninger previously worked at Lockheed Martin as a senior mechanical engineer in defense and aerospace, then in thermal imaging, night vision, and infrared cameras; he also holds an MBA. Program & IT Lead Amina Venton specializes in full-stack software development, NLP, and automation. Notable investors include Mark Templeton (former President and CEO of Citrix Systems 2001-2015, CEO of Digital Ocean) who provided an investment memo, and Sunil Potti (Venture Partner at Wing VC, former head of Google's security business for 6+ years, former Chief P&D Officer at Nutanix).

FAQ